SCHEMBL4987220

SCHEMBL4987220

CC(C)(C)c1ccc(C(=O)Nc2ccc3cc(C(=O)O)ccc3n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ MTTP P55157 2/20 0.53
▸ NPC1 O15118 5/20 0.52
▸ RAB9A P51151 5/20 0.52
▸ DEGS1 O15121 1/20 0.51
▸ MAPT P10636 3/20 0.50
▸ TRPV1 Q8NER1 2/20 0.49
▸ EPHX2 P34913 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ MAP3K5 Q99683 2/20 0.47
▸ KCNK9 Q9NPC2 1/20 0.47
▸ NR1H4 Q96RI1 2/20 0.47
▸ PPARG P37231 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3175315 0.86 MTTP (0.73) MTTPNR1H4PPARG
SCHEMBL4981961 0.83 MTTP (0.60) MEN1KMT2AMTTPNPC1RAB9A
SCHEMBL4982046 0.83 MTTP (0.56) MEN1KMT2AMTTPNPC1RAB9A
SCHEMBL5666303 0.83 MTTP (0.56) MTTPTRPV1
SCHEMBL4986089 0.81 MTTP (0.53) MTTPNPC1RAB9ANR1H4PPARG
SCHEMBL31188316 0.80 KDM4E (0.47) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL23535706 0.79 TDP1 (0.43) MEN1KMT2AMTTPNPC1RAB9A
SCHEMBL31504571 0.79 TDP1 (0.43) MEN1KMT2AMTTPNPC1RAB9A
SCHEMBL2671343 0.78 HCAR3 (0.54) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL28340991 0.76 RAB9A (0.63) MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368573-B2 Triamide-substituted heterobicyclic compounds PFIZER INC. (US) 2008-05-06 — — US disclosed
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS BERTINATO PETER 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS APOB, MTPN, CTRB1 MEN1 1637/4885KMT2A 4384/4885MTTP 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback